A Study of HS-10504 in Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)

Hansoh Pharma

Status and phase: Enrolling; Phase 1

Conditions: Locally Advanced or Metastatic NSCLC

Treatments: Drug: HS-10504

Study type: Interventional

Funder types: Industry

Identifiers

NCT06461156

HS-10504-101

Details and patient eligibility

About

HS-10504 is a fourth-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor targeting EGFR C797S mutation. This study will evaluate the safety, tolerability, pharmacokinetics and efficacy of HS-10504 in Chinese locally advanced or metastatic NSCLC.

Enrollment: 230 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Males or females, aged ≥ 18 years.
• Subjects with histologically or cytologically confirmed locally advanced or metastatic NSCLC
• Progressive disease on or after prior treatment with EGFR-TKIs.
• Enrollment will be restricted to participants with evidence of EGFR-positive in tumor as determined by local or central testing.
• At least 1 target lesion according to RECIST 1.1.
• ECOG PS score: 0-1.
• Estimated life expectancy> 12 weeks.
• Men or women should be using adequate contraceptive measures throughout the study.
• Women must have the evidence of non-childbearing potential.
• Signed and dated Informed Consent Form.

Exclusion criteria

• Subjects with known oncogenic driver genes other than EGFR.

• Subjects with mixed cell histologic or with phenotypic transformation.

• Treatment with any of the following:

  1. Prior or concurrent treatment with fourth-generation EGFR tyrosine kinase inhibitors.
  2. Cytotoxic chemotherapy, any other investigational drugs, traditional Chinese medicine with anti-tumor indications, or other anti-tumor drugs within 14 days prior to the first dose of HS-10504 or require continued treatment with these drugs during the study.
  3. Any local radiotherapy 2 weeks prior to the first dose of study treatment; have received irradiation of more than 30% of bone marrow prior to the first dose
  4. Uncontrolled pleural effusion or ascites or pericardial effusion.
  5. Major surgery within 4 weeks before the first dose.
  6. CNS metastases with symptomatic or active progression.

• Subjects who have any grade ≥2 residual toxicities from prior therapies.

• Subjects who have history of other primary malignancies.

• Inadequate bone marrow reserve or hepatic and renal functions.

• Subjects with severe or poorly controlled diabetes, cardiovascular diseases or hypertension; subjects with severe arteriovenous thrombotic events, severe infection, clinically significant bleeding symptoms or clinically significant gastrointestinal dysfunction.

• Hypersensitivity to any ingredient of HS-10504.

• Moderate to severe pulmonary diseases.

• Prior history of significant neurological or mental disorders.

• Women who are breastfeeding or pregnant or planned to be pregnant during the study period.

• Unlikely to comply with study procedures, restrictions, and requirements in the opinion of the investigator.

• Any disease or condition that, in the opinion of the investigator, would compromise subject safety or interfere with study assessments.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

230 participants in 1 patient group

HS-10504

Experimental group

Description:

Subjects with advanced or metastatic NSCLC will be enrolled in dose-escalation stage. Dose escalation of HS-10504 will be done to determine maximum tolerated dose(Dose Escalation Stage). Depending on data obtained from the dose-escalation stage, dose expansion may proceed with in subjects with advanced or metastatic NSCLC having an EGFR C797S mutation. It can be conducted at the potentially safe and effective doses(Dose Expansion Stage).

Treatment:

Drug: HS-10504